论文部分内容阅读
目的通过利用常规治疗(硝酸酯类、β受体阻滞剂,钙拮抗剂及小剂量阿斯匹林等)和加用小剂量尿激酶及低分子量肝素治疗不稳定型心绞痛(UAP)的对比来判定两种方法疗效。方法资料来源于我院的58例UAP病人,把他们分成对照组(常规治疗)及治疗组(在常规治疗的基础之上加用小剂量尿激酶及低分子肝素),一周之后观察疗效。结果治疗组非常明显,较对照组有明显差异,其中治疗组无一例死亡,而对照组在治疗过程中有2例发生心梗而死亡。结论通过上诉结果说明:加用小剂量尿激酶及低分子肝素治疗UAP可显著提高疗效,缓解症状,改善病人预后,提高生活质量,减少心肌梗死和死亡的发生。
OBJECTIVE: To compare the efficacy and safety of the treatment of unstable angina pectoris (UAP) with conventional therapy (nitrates, beta blockers, calcium antagonists and low-dose aspirin) and with low-dose urokinase and low molecular weight heparin To determine the efficacy of two methods. Methods The data were collected from 58 UAP patients in our hospital. They were divided into control group (conventional treatment) and treatment group (low-dose urokinase and low molecular weight heparin on the basis of conventional treatment), and the effect was observed after one week. The results of the treatment group is very obvious, compared with the control group were significantly different, including no death in the treatment group, while the control group in the course of treatment, 2 cases of myocardial infarction and death. Conclusion The result of the appeal shows that UAP plus low-dose urokinase and LMWH can significantly improve the curative effect, relieve the symptoms, improve the prognosis of patients, improve the quality of life and reduce the incidence of myocardial infarction and death.